Clinical
Juan Carlos Zerpa Acosta & Gurukripa N. Kowlgi
J Interv Card Electrophysiol 2024.
This is an independent Commentary discussing AtriAN’s previously published FIH study. It specifically focuses on the potential for the AtriAN treatment to be also used in open-chest cardiac surgery as a means to prophylactically treat post-operative AF (POAF). POAF is costing healthcare systems over $1 billion annually and current prevention approaches are largely unsuccessful.